Pre-Exposure Prophylaxis (PrEP): The science and experiences with practical application

Printer-friendly version
Session ID: 
High Impact Prevention
Session Description: 

In the past 4 years, pre-exposure prophylaxis (PrEP), has been shown to be effective for high risk men who have sex with men (MSM), heterosexuals, and for injection drug users. For the 1st time in 2012, the US Food and Drug Administration (FDA) approved for daily use by uninfected adults to help prevent the sexual acquisition of HIV, a drug that has been commercially available as an HIV treatment since 2004.

For some individuals at high risk for HIV infection, PrEP may represent a much-needed additional prevention method intended to be used in combination with other methods to reduce the risk of getting HIV infection. If it is delivered effectively and targeted to those at highest risk, PrEP may play a role in helping to reduce the significant continuing toll of new HIV infections in the United States. Now that efficacy has been demonstrated in the research setting, the challenge is to plan and implement PrEP in real world settings rather than in a research context.

This session is intended to provide an overview of the science, and experiences with planning for or the use of PrEP in clinical settings in the US. The session will open with a review of the science of PrEP--- what’s occurred over the past 4 years and an update on the new studies that will provide additional information about the safe and effective use of this prevention tool. Next, a health department will provide information on their efforts to support the implementation of PrEP in their jurisdiction. Lastly, a community based organization (CBO) or health center speaker will present their efforts in the practical application of PrEP. Health Department and CBO/health center speakers will highlight both opportunities as well as challenges they have experienced in the practical implementation of PrEP. Significant time will be allocated for audience input, questions, and discussion about experiences with the planning, implementation, and introduction of PrEP as a clinically-delivered HIV prevention service.


Dawn Smith, Centers for Disease Control and Prevention, Atlanta, GA; Charles Gonzalez, New York State Department of Health/AIDS Institute, Albany, NY; Alex Gonzalez, Fenway Health Center, Boston, MA

Time Slot: 
Mon, 09/09/2013 - 2:30pm - 4:00pm
Empire C, Level 2
Presentation Level: 

The National Minority AIDS Council (NMAC), a 501(c)3 organization, develops leadership in communities of color to end the HIV/AIDS epidemic. Since 1987, NMAC has advanced this mission through a variety of programs and services, including: a public policy education program, national and regional training conferences, a treatment and research program, numerous electronic and materials and a website: NMAC also serves as an association of AIDS service organizations providing valuable information to communitybased organizations, hospitals, clinics and other groups assisting individuals and families affected by the AIDS epidemic.

NMAC's advocacy efforts are funded through private funders and donors only.

For more information, contact:
NMAC * 1931 13th Street NW, Washington, DC 20009-4432
Tel: (202) 483-6622 * Fax: (202) 483-1135 * E-mail:

Contact Us | Privacy Policy